Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price hit a new 52-week low on Tuesday . The company traded as low as $190.47 and last traded at $194.00, with a volume of 107092 shares trading hands. The stock had previously closed at $208.35.
Genmab A/S Stock Down 0.2 %
The business's 50 day simple moving average is $210.08 and its two-hundred day simple moving average is $235.12. The stock has a market cap of $13.05 billion, a P/E ratio of 18.99 and a beta of 1.04.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
